Perspective Therapeutics prices $175M offering of common stock and pre-funded warrants at $3.79/share

Perspective Therapeutics, Inc.

Gross proceeds ~$175M from 39,576,088 shares at $3.79/share and 6,598,046 pre-funded warrants at $3.789.
Offering closed Feb 3, 2026; net proceeds to fund clinical development, manufacturing, and general corp purposes.
Underwriters include Piper Sandler, UBS, Oppenheimer, Truist, and LifeSci Capital.
Participation from Commodore Capital, TCGX, Spruce Street Capital, Surveyor Capital (Citadel), and others.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Perspective Therapeutics, Inc. entered into Underwriting Agreement with Piper Sandler & Co. and UBS Securities LLC, as representatives of the underwriters named therein valued at approximately $175 million (effective 2026-02-02).

Action: entry
Agreement: underwriting
Counterparty: Piper Sandler & Co. and UBS Securities LLC, as representatives of the underwriters named therein
Value: approximately $175 million
Effective: 2026-02-02

Exact text from the filing

On February 2, 2026, Perspective Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. and UBS Securities LLC, as representatives of the underwriters named therein (the “Underwriters”), in connection with its previously announced underwritten offering (the “Offering”) of 39,576,088 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and, in lieu of Shares to certain investors, pre-funded warrants (the “Pre-Funded Warrants”) to purchase 6,598,046 shares of Common Stock.

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-035508

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.